In this review:
This review discusses the pH-dependent release formulation and benefits of enteric coated/gastroresistant
mesalazine (Asacol™) and its role in inducing and maintaining remission in mild to moderate ulcerative colitis (UC). All Asacol™ formulations (tablets and suppositories) are now funded in NZ, including the 800mg tablet which was listed in January 2016.
Expert commentary on the use of Asacol™ from the clinical practice perspective is provided by
gastroenterologist Dr David Rowbotham (Auckland City Hospital, Endoscopy Auckland and MacMurray
Centre, Auckland).
Download PDF